A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapy For Patients With Relapsed Follicular Non-Hodgkins Lymphoma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Iodine-131 tositumomab (Primary) ; Ibritumomab tiuxetan; Rituximab; Tositumomab
Indications Follicular lymphoma
Focus Therapeutic Use
Sponsors GlaxoSmithKline; GSK

01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
15 May 2014 Status changed from discontinued to completed as reported by ClinicalTrials.gov record (NCT00268983)..
15 May 2014 Status changed from discontinued to completed as reported by ClinicalTrials.gov record (NCT00268983)..

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com